People born 1947-1951 invited for COVID-19 vaccination starting 6 April Starting Tuesday 6 April, the first people in the next age group will receive an invitation from RIVM for a COVID-19 vaccination. These people were born in the years from 1947 through 1951.
Single vaccination after COVID-19 infection within the past six months Starting today, people who tested positive for COVID-19 in the past six months can indicate when scheduling a vaccination appointment that they only want one vaccine dose.
Screening for chronic Q-fever is only cost-effective for specific groups RIVM has investigated for which groups screening for chronic Q-fever might be cost-effective.
Pneumococcal disease in the elderly The Health Council of the Netherlands is preparing an advice on pneumococcal vaccination for the elderly on request of the Ministry of Health, Welfare and Sport.
Statement on health care spending Down syndrome Recently a tweet containing a video from a Dutch tv-show about Down syndrome caused a lot of turmoil on Twitter.
Temporary dermal fillers prove harmless RIVM has conducted a market surveillance study of 26 so-called non-permanent fillers. All 26 products proved to be harmless.
Slight increase of the number of tuberculosis patients in 2016 For the second consecutive year, the number of tuberculosis (TB) patients in the Netherlands increased.
Promising biobased alternatives to controversial polar aprotic solvents There are a number of promising biobased alternatives to controversial polar aprotic solvents, as revealed in a report from Wageningen Food & Biobased Research commissioned by RIVM .
Risk of degradation of European ecosystems by air pollution is decreasing The number of natural areas in Europe that are threatened by air pollution will decrease between 2005 and 2020.
RIVM participates in large EU project to head up global fight against infectious diseases COMPARE, a large EU project intends to speed up the detection of, and response to disease outbreaks among humans and animals worldwide, through the use of new genome technology.